Immunological overlap stratification in anti-GBM disease: prognostic differences and serological correlations—a single-center retrospective cohort study - Report - MDSpire
Advertisement
Immunological overlap stratification in anti-GBM disease: prognostic differences and serological correlations—a single-center retrospective cohort study
Clinical Report: Stratification of Immunological Overlap in Anti-GBM Disease
Overview
This study investigates the clinical characteristics of anti-GBM disease with overlapping autoimmune profiles. It highlights significant differences in antibody titers among distinct patient cohorts.
Background
Anti-GBM disease is a serious autoimmune condition primarily affecting the kidneys, often presenting with rapidly progressive glomerulonephritis. The coexistence of anti-GBM antibodies with other autoimmune antibodies, such as ANCA, complicates diagnosis and treatment, necessitating a deeper understanding of these overlaps for improved patient management.
Data Highlights
Group
Mean Age at Onset
Anti-GBM Antibody Titer (Median)
Classic anti-GBM
Not specified
141.20
ANCA-anti-GBM double-positive
Highest
104.25
Anti-GBM-non-ANCA overlap
Not specified
181.70
Key Findings
The study included 67 patients with anti-GBM disease, stratified into three groups based on serological profiles.
The ANCA-anti-GBM double-positive group had the highest mean age at onset.
Significant differences in baseline anti-GBM antibody titers were observed among the groups (p = 0.044).
No significant differences were noted in clinical characteristics, renal pathology, or treatment regimens across groups.
Early survival outcomes varied, with the ANCA-anti-GBM group showing the poorest early survival.
Relying solely on anti-GBM antibody titers for prognosis is deemed inappropriate.
Clinical Implications
The findings indicate that the presence of overlapping autoantibodies should be considered when assessing prognosis in anti-GBM disease.
Conclusion
This study identifies the complexity of anti-GBM disease and the importance of understanding serological profiles.
